{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.767","upperLimit":"0.869","value":"0.825"},{"groupId":"OG001","lowerLimit":"0.752","upperLimit":"0.856","value":"0.810"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"174"},{"groupId":"OG001","value":"174"}],"units":"Participants"}],"description":"Kaplan-Meier estimates for the probability (expressed as a percentage) of participants that survived at the end of Month 6 from randomization are presented.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were administered azacitidine 75 mg/m\\^2 IV or SC injection on Days 1 to 5, Days 8 and 9, in 28-day treatment cycles until disease progression or unacceptable toxicity or up to a maximum of 63 cycles.","id":"OG000","title":"Azacitidine 75 mg/m^2"},{"description":"Participants were administered azacitidine 75 mg/m\\^2 IV or SC injection on Days 1 to 5, Days 8 and 9 and pevonedistat 20 mg/m\\^2 IV infusion, on Days 1, 3, and 5 in 28-day treatment cycles until disease progression or unacceptable toxicity or up to a maximum of 63 cycles.","id":"OG001","title":"Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2"}],"paramType":"NUMBER","populationDescription":"ITT Population included all participants who were randomized. Overall number analyzed is the number of participants with data available for analyses.","reportingStatus":"POSTED","timeFrame":"Month 6","title":"Kaplan-Meier Estimates of Six-Month Survival Rate","type":"SECONDARY","unitOfMeasure":"percentage probability"}